Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Germing, U
Right arrow Articles by Haas, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Germing, U
Right arrow Articles by Haas, R
Haematologica, Vol 91, Issue 12, 1596-1604
Copyright © 2006 by Ferrata Storti Foundation

Comparative Study

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes

U Germing, C Strupp, A Kuendgen, S Isa, S Knipp, B Hildebrandt, A Giagounidis, C Aul, N Gattermann, and R Haas

Department of Hematology, Oncology and Clinical Immunology Heinrich-Heine-University Moorenstr. 5, 40225 Dusseldorf, Germany. germing@med.uni-duesseldorf.de

BACKGROUND AND OBJECTIVES: The aim of this study was a prospective validation of the World Health Organization (WHO) proposals for the classification of myelodysplastic syndromes (MDS) with respect to their prognostic relevance. DESIGN AND METHODS: We classified 1095 patients with MDS diagnosed at our institution between November 1999 and December 2004 according to French-American-British (FAB) and WHO criteria by central morphologic review. The study was not population-based, but included all newly diagnosed patients from different regions in Germany. Patients were followed for survival and disease evolution to acute myeloid leukemia (AML) through December 31th, 2005. RESULTS: According to the WHO classification, there were 89 cases of refractory anemia (RA), 293 of refractory cytopenias with multilineage dysplasia (RCMD), 31 RA with ringed sideroblasts (RARS), 139 RCMD with ringed sideroblasts (RCMD-RS), 142 RA with excess blasts (RAEB) I and 149 RAEB II and 52 patients with 5q- syndrome. The median survival of patients with RA or RARS was not reached, the median survival of patients with RCMD was 31 months, that of patients with RCMD-RS was 28 months, that of 5q- patients was 40 months, of RAEB I 27 months and of RAEB II 12 months. The cumulative risk of AML evolution 2 years after diagnosis was 0% in RA and RARS, 8% in 5q-, 9% in RCMD, 12% in RCMD-RS, 13% in RAEB I and 40% in RAEB II. The number of high-risk karyotypes was lower in patients with RA/RARS than in those with RCMD/RCMD-RS and RAEB I/RAEB II. Karyotype findings were major prognostic variables. INTERPRETATION AND CONCLUSIONS: The WHO classification is feasible and provides valuable prognostic information, even in a short-term prospective study. Together with cytogenetic data and other prognostic parameters, the WHO classification is very useful for clinical decision making.


This article has been cited by other articles:


Home page
 BloodHome page
E. P. Alessandrino, M. G. Della Porta, A. Bacigalupo, M. T. Van Lint, M. Falda, F. Onida, M. Bernardi, A. P. Iori, A. Rambaldi, R. Cerretti, et al.
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Blood, August 1, 2008; 112(3): 895 - 902.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. T. Bowen, P. Fenaux, E. Hellstrom-Lindberg, and T. de Witte
Time-Dependent Prognostic Scoring System for Myelodysplastic Syndromes Has Significant Limitations That May Influence Its Reproducibility and Practical Application
J. Clin. Oncol., March 1, 2008; 26(7): 1180 - 1180.
[Full Text] [PDF]

Home page
 JCOHome page
L. Malcovati, M. Cazzola, and U. Germing
In Reply
J. Clin. Oncol., March 1, 2008; 26(7): 1181 - 1182.
[Full Text] [PDF]

Home page
 BloodHome page
D. Haase, U. Germing, J. Schanz, M. Pfeilstocker, T. Nosslinger, B. Hildebrandt, A. Kundgen, M. Lubbert, R. Kunzmann, A. A. N. Giagounidis, et al.
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
Blood, December 15, 2007; 110(13): 4385 - 4395.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. C. Link, G. Kunter, Y. Kasai, Y. Zhao, T. Miner, M. D. McLellan, R. E. Ries, D. Kapur, R. Nagarajan, D. C. Dale, et al.
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia
Blood, September 1, 2007; 110(5): 1648 - 1655.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Malcovati, U. Germing, A. Kuendgen, M. G. Della Porta, C. Pascutto, R. Invernizzi, A. Giagounidis, B. Hildebrandt, P. Bernasconi, S. Knipp, et al.
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
J. Clin. Oncol., August 10, 2007; 25(23): 3503 - 3510.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
U. Germing, C. Strupp, S. Knipp, A. Kuendgen, A. Giagounidis, B. Hildebrandt, C. Aul, R. Haas, N. Gattermann, and J. M. Bennett
Chronic myelomonocytic leukemia in the light of the WHO proposals
Haematologica, July 1, 2007; 92(7): 974 - 977.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. Melchert and A. F. List
Management of RBC-Transfusion Dependence
Hematology, January 1, 2007; 2007(1): 398 - 404.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.